Literature DB >> 15613425

Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

Serge L Ferrari1, Jean-Philippe Bonjour, René Rizzoli.   

Abstract

The renal handling of inorganic phosphate (Pi) is controlled not only by PTH, but also by hitherto undetermined mechanisms dependent on phosphate intake. Recently, fibroblast growth factor (FGF)-23 was identified as a novel phosphaturic factor in tumor-induced osteomalacia and autosomal-dominant hypophosphatemic rickets. We hypothesized that phosphate intake could influence FGF-23 concomitantly to the changes in renal Pi handling. Twenty-nine healthy males were subjected to a 5-d low-phosphate diet and a phosphate binder, followed by a high-phosphate diet including supplements. Concomitant modifications in calcium intake allowed minimizing PTH changes in response to dietary phosphate. Serum FGF-23 levels significantly decreased on the low-phosphate diet, then increased with the oral phosphate load. Changes in FGF-23 were positively correlated with changes in 24-h urinary Pi excretion and negatively correlated with changes in the maximal tubular reabsorption of Pi and 1,25(OH)(2)D(3) (calcitriol), whereas PTH was not. In multivariate analysis, changes in FGF-23 remained the most significantly correlated to changes in 1,25(OH)(2)D(3) and maximal tubular reabsorption of Pi. Moreover, FGF-23 was positively correlated to serum osteocalcin, a marker of osteoblastic activity. In summary, FGF-23 was inversely related to renal Pi transport and serum calcitriol levels in healthy young men. These data suggest that FGF-23 may be implicated in the physiological regulation of Pi homeostasis in response to dietary phosphate changes, independent of PTH.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15613425     DOI: 10.1210/jc.2004-1039

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  174 in total

Review 1.  Biology of Fibroblast Growth Factor 23: From Physiology to Pathology.

Authors:  Marie Courbebaisse; Beate Lanske
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

Review 2.  Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho).

Authors:  Emily G Farrow; Erik A Imel; Kenneth E White
Journal:  Best Pract Res Clin Rheumatol       Date:  2011-10       Impact factor: 4.098

3.  Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease.

Authors:  Jessica Houston; Kelsey Smith; Tamara Isakova; Nicole Sowden; Myles Wolf; Orlando M Gutiérrez
Journal:  J Ren Nutr       Date:  2012-03-09       Impact factor: 3.655

Review 4.  Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.

Authors:  L Darryl Quarles
Journal:  Nat Rev Endocrinol       Date:  2012-01-17       Impact factor: 43.330

5.  FGF23 beyond mineral metabolism: a bridge to cardiovascular disease.

Authors:  Tobias E Larsson
Journal:  Clin J Am Soc Nephrol       Date:  2011-12       Impact factor: 8.237

6.  FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.

Authors:  Victoria Shalhoub; Edward M Shatzen; Sabrina C Ward; James Davis; Jennitte Stevens; Vivian Bi; Lisa Renshaw; Nessa Hawkins; Wei Wang; Ching Chen; Mei-Mei Tsai; Russell C Cattley; Thomas J Wronski; Xuechen Xia; Xiaodong Li; Charles Henley; Michael Eschenberg; William G Richards
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

7.  Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23.

Authors:  Sherri-Ann M Burnett-Bowie; Benjamin Z Leder; Maria P Henao; Chantel M Baldwin; Douglas L Hayden; Joel S Finkelstein
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-02       Impact factor: 8.237

8.  Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone.

Authors:  Nancy S Krieger; Christopher D Culbertson; Kelly Kyker-Snowman; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-30

Review 9.  Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease.

Authors:  Julia J Scialla; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2014-04-01       Impact factor: 28.314

10.  Interaction of Serum Phosphate with Age as Predictors of Cardiovascular Risk Scores in Stable Renal Transplant Recipients.

Authors:  Jillian Kerry; Holly Mansell; Hamdi Elmoselhi; Mike Moser; Ahmed Shoker
Journal:  Int J Angiol       Date:  2016-12-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.